191 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27774132	20	Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.	Takeda Pharmaceutical
27720325	5	Novel approach of fragment-based lead discovery applied to renin inhibitors.	Takeda Pharmaceutical
27687967	17	Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.	Takeda Pharmaceutical
26363506	44	Discovery of highly potent renin inhibitors potentially interacting with the S3' subsite of renin.	China Pharmaceutical University
25782742	76	trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.	Novartis Pharma
25754490	44	trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.	Novartis Pharma
25728416	25	Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors.	Merck Research Laboratories
25086681	57	Structure-based optimization of non-peptidic Cathepsin D inhibitors.	Merck
25050166	58	Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.	Novartis Institutes For Biomedical Research
25363711	62	Inhibitors ofß-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).	Amgen
23993670	2	Novel BACE1 inhibitors with a non-acidic heterocycle at the P1' position.	Kyoto Pharmaceutical University
24054120	5	The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations.	Novartis Institutes For Biomedical Research
23886807	39	Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.	Daiichi Sankyo
23598247	92	Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor.	Daiichi Sankyo
23590342	105	ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.	F. Hoffmann-La Roche
23425156	24	The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.	Novartis Pharma
23360239	19	A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.	Novartis Pharma
3316655	34	Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin.	Sanofi Recherche
22200345	7	An integrated computational workflow for efficient and quantitative modeling of renin inhibitors.	Sanofi Us
	4	Retro-Inverso Tripeptide Renin Inhibitors	TBA
23122821	26	Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors.	Daiichi Sankyo
21381769	56	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.	Universite£
24900544	8	Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor.	TBA
22621689	1	Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.	National Hellenic Research Foundation
22726934	58	Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors.	Daiichi Sankyo
24900262	31	Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.	TBA
22450130	87	Design and synthesis of potent, isoxazole-containing renin inhibitors.	Merck Frosst Centre For Therapeutic Research
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
19358611	103	Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.	Actelion Pharmaceuticals
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
8120867	70	Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.	E. Merck Darmstadt
8474103	123	Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.	Abbott Laboratories
8340909	14	Excursions in drug discovery.	Merck Research Laboratories
1433190	43	Highly potent, orally active diester macrocyclic human renin inhibitors.	Merck Research Laboratories
1635057	48	Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.	Parke-Davis Pharmaceutical Research Division of Warner-Lambert
1732531	88	Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.	Warner-Lambert
2066983	10	Determination of dissociation constants of high affinity (pM) human renin inhibitors: application to analogues of ditekiren (U-71,038).	Upjohn Laboratories
2066966	32	Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.	Warner-Lambert
2002469	80	Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.	Merck Sharp and Dohme Research Laboratories
1956045	88	Substrate analogue renin inhibitors containing replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites.	E. Merck Darmstadt
2202828	28	Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp.	Ici Pharmaceuticals Group
2194033	33	Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action.	Abbott Laboratories
2184238	14	Renin inhibitory peptides. A beta-aspartyl residue as a replacement for the histidyl residue at the P-2 site.	Upjohn
2120440	23	Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.	Kissei Pharmaceutical
2566685	47	Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements.	University of Wisconsin-Madison
2657067	23	Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue.	Abbott Laboratories
3045320	37	Design of rat renin inhibitory peptides.	Massachusetts General Hospital
3290486	7	Synthesis and renin inhibitory activity of angiotensinogen analogues having dehydrostatine, Leu psi [CH2S]Val, or Leu psi [CH2SO]Val at the P1-P1' cleavage site.	Upjohn
3290485	7	Conformationally constrained renin inhibitory peptides: gamma-lactam-bridged dipeptide isostere as conformational restriction.	Upjohn
3275777	34	Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.	Upjohn
3298652	19	Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.	TBA
3546690	7	alpha-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model.	TBA
3118024	35	Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement.	Abbott Laboratories
3543358	96	Pepstatin analogues as novel renin inhibitors.	TBA
3531518	17	Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.	TBA
3531517	17	Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.	TBA
3906131	61	Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.	TBA
3906126	10	Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.	TBA
6352942	10	Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid.	TBA
7045370	8	Renin inhibitors. Substitution of the leucyl residues of Leu-Leu-Val-Phe-OCH3 with 3-amino-2-hydroxy-5-methylhexanoic acid.	TBA
6267277	15	Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension.	TBA
	37	Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties	TBA
22325946	36	3,4-Diarylpiperidines as potent renin inhibitors.	Merck Frosst Center For Therapeutic Research
22130130	19	Discovery of pyrrolidine-basedß-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency.	Merck Research Laboratories
22071301	115	Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.	Merck Frosst Centre For Therapeutic Research
21641209	120	Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.	Merck Frosst Centre For Therapeutic Research
21840218	62	Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.	Deutschland
21840215	51	Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.	Sanofi-Aventis Deutschland
21741239	35	Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.	Vitae Pharmaceuticals
21708467	19	Synthesis, biological evaluation and docking studies of octane-carboxamide based renin inhibitors with extended segments toward S3' site of renin.	China Pharmaceutical University
21621998	110	Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.	Merck Frosst Centre For Therapeutic Research
21497958	12	Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches.	Gyeongsang National University (Gnu)
21429746	88	The discovery and synthesis of potent zwitterionic inhibitors of renin.	Merck Frosst Centre For Therapeutic Research
21112780	30	Design and synthesis of potent macrocyclic renin inhibitors.	Medivir
20731374	65	Direct renin inhibitors as a new therapy for hypertension.	Novartis Pharmaceuticals
20880704	200	Design and synthesis of aminohydantoins as potent and selective humanß-secretase (BACE1) inhibitors with enhanced brain permeability.	Pfizer
20850300	45	Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.	Sanofi-Aventis Deutschland
20843690	60	Piperidine-based renin inhibitors: upper chain optimization.	Actelion Pharmaceuticals
20843686	99	Design and optimization of new piperidines as renin inhibitors.	Actelion Pharmaceuticals
20728350	41	Identification of a new biaryl scaffold generating potent renin inhibitors.	Merck Frosst Center For Therapeutic Research
20673718	5	Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.	Merck Frosst Centre For Therapeutic Research
20206513	35	Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.	Merck Frosst Centre For Therapeutic Research
19853442	35	New classes of potent and bioavailable human renin inhibitors.	Actelion Pharmaceuticals
19959358	57	Optimization of orally bioavailable alkyl amine renin inhibitors.	Vitae Pharmaceuticals
19968289	201	Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.	Wyeth Research
19757823	98	Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.	Wyeth Research
19493591	7	Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.	University of Toyama
19615901	52	The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.	Nagasaki International University
	18	Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin	TBA
	23	Novel low molecular renin inhibitors which show good oral blood pressure lowering effects in marmosets	TBA
	16	Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties. A novel strategy towards small non-peptide renin inhibitors	TBA
	3	Synthesis of α-hydroxy statine through a facially selective osmylation of a chiral α-amido crotonate	TBA
	9	Rational design, synthesis, and X-ray structure of renin inhibitors with extended P1 sidechains	TBA
	3	CP-71,362, an unusually potent inhibitor of rat and dog renin	TBA
	11	Tetrahydroisoquinoline as a phenylalanine replacement in renin inhibitors	TBA
	13	Preparation of a novel series of phosphonate norstatine renin inhibitors	TBA
	4	Design and synthesis of a prototypical non-peptidic inhibitor model for the enzme renin	TBA
	15	The identification of a novel renin inhibitor of equivalent efficacy following oral or intravenous administration.	TBA
	22	Novel pseudosymmetric inhibitors of HIV-1 protease	TBA
	24	Diol sulfonamides: A potent and novel class of inhibitors of human renin	TBA
	6	Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→ P3)-P1' sites	TBA
	12	MDL 74147, a novel selective and soluble inhibitor of human renin. Synthesis, structure-activity relationship, species and protease selectivities.	TBA
	38	Conformationally restricted peptide isosteres. 2.1 Synthesis and in vitro potency of dipeptide renin inhibitors employing a 2-alkylsulfonyl-3-phenylcyclopropane carboxamide as a P3 amino acid replacement	TBA
19323562	14	2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.	Abbott Laboratories
17482814	37	Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.	Merck Research Laboratories
16143527	32	Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors.	Pfizer
15837327	12	Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors.	Pfizer
14741251	12	Rational design and synthesis of selective BACE-1 inhibitors.	Merck Research Laboratories
32247750	1	Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.	Annamalai University
10360745	40	Piperidine-renin inhibitors compounds with improved physicochemical properties.	F. Hoffmann-La Roche
10360744	26	Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site.	F. Hoffmann-La Roche
31589043	91	Discovery of AM-6494: A Potent and Orally Efficacious ?-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.	TBA
31188592	39	Why Some Targets Benefit from beyond Rule of Five Drugs.	Boston University
8474102	29	Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-725	Abbott Laboratories
8474101	30	Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides.	Abbott Laboratories
8410992	35	Renin inhibitors containing a pyridyl amino diol derived C-terminus.	Hoechst
8410973	75	Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation.	University of Florida
8254610	14	Analyses of ligand binding in five endothiapepsin crystal complexes and their use in the design and evaluation of novel renin inhibitors.	Warner-Lambert
7932521	81	Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.	Abbott Laboratories
7752198	8	Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human renin.	Boehringer Ingelheim Pharmaceuticals
7473584	16	alpha-Hydroxy phosphinyl-based inhibitors of human renin.	Bristol-Myers Squibb Pharmaceutical Research Institute
6993683	8	N-(alpha-Hydroxyalkanoyl) derivatives of Leu-Val-Phe-OCH3 as inhibitors of renin.	TBA
6767029	14	Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effects of structure on inhibition of pepsin and renin.	TBA
6384520	9	Inhibition of renin by substrate analogue inhibitors containing the olefinic amino acid 5(S)-amino-7-methyl-3(E)-octenoic acid.	TBA
3906130	5	A uniquely potent renin inhibitor and its unanticipated plasma binding component.	TBA
3882966	28	Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.	TBA
3312604	33	Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond.	Abbott Laboratories
3309316	50	Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini.	Merck Sharp & Dohme Research Laboratories
3309315	8	alpha,alpha-Difluoro-beta-aminodeoxystatine-containing renin inhibitory peptides.	Upjohn
3309313	48	Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond.	Abbott Laboratories
3305947	7	Fluoro ketone containing peptides as inhibitors of human renin.	TBA
3305946	31	New inhibitors of human renin that contain novel Leu-Val replacements.	TBA
3302256	45	Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides.	TBA
3295239	9	Renin inhibitors. Design of angiotensinogen transition-state analogues containing novel. (2R,3R,4R,5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid.	TBA
3279210	19	Renin inhibitors containing psi[CH2O] pseudopeptide inserts.	Upjohn
3279206	16	New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.	Abbott Laboratories
3276890	28	Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen.	Abbott Laboratories
3143010	28	Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability.	Abbott Laboratories
3143009	50	Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.	Abbott Laboratories
3137345	19	Synthesis and biological activity of some transition-state inhibitors of human renin.	Ciba-Geigy
3127587	33	New human renin inhibitors containing an unnatural amino acid, norstatine.	Kissei Pharmaceutical
3126296	43	Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.	University of Wisconsin
3050088	47	Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency.	Merck Sharp & Dohme Research Laboratories
28985999	74	Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.	Glaxosmithkline
2661820	18	Renin inhibitors. Synthesis of transition-state analogue inhibitors containing phosphorus acid derivatives at the scissile bond.	Ciba-Geigy Pharmaceuticals Division
2405159	49	Renin inhibitors containing isosteric replacements of the amide bond connecting the P3 and P2 sites.	Warner-Lambert
2404121	20	Renin inhibitors based on dipeptide analogues. Incorporation of the hydroxyethylene isostere at the P2/P3 sites.	Abbott Laboratories
2202829	18	Inhibitors of human renin. Cyclic peptide analogues containing a D-Phe-Lys-D-Trp sequence.	Ici Pharmaceuticals Group
2197411	13	Thermodynamics of the interaction of inhibitors with the binding site of recombinant human renin.	Upjohn
2187994	40	Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site.	Abbott Laboratories
29754833	73	Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.	Takeda Pharmaceutical
2118184	14	1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives.	Ici Pharmaceuticals Group
2118183	18	1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives.	Ici Pharmaceuticals Group
2105396	14	New inhibitors of renin that contain novel phosphostatine Leu-Val replacements.	Abbott Laboratories
28601508	34	Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations.	Bioleap
1995887	14	Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in a human renin infused rat model and in conscious sodium-depleted monkeys.	Upjohn
1992151	10	Design of a well-absorbed renin inhibitor.	Abbott Laboratories
1992113	12	1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 3.1 Synthesis and biological properties of aminodeoxystatine and difluorostatone derivatives.	Ici Pharmaceuticals Group
1901910	87	New inhibitors of human renin that contain novel replacements at the P2 site.	Warner-Lambert
1895289	8	Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors.	Merck Sharp and Dohme Research Laboratories
1738148	16	Renin inhibitory pentols showing improved enteral bioavailability.	Hoechst
1597860	24	Renin inhibitors containing C-termini derived from mercaptoheterocycles.	Merck Sharp & Dohme Research Laboratories
1588555	83	C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.	Abbott Laboratories
1588554	66	Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement.	Abbott Laboratories
1588553	32	1,2,3-trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors.	University of Texas
1552498	55	Renin inhibitors containing alpha-heteroatom amino acids as P2 residues.	Warner-Lambert
1548675	10	Synthesis and use of 3-amino-4-phenyl-2-piperidones and 4-amino-2-benzazepin-3-ones as conformationally restricted phenylalanine isosteres in renin inhibitors.	Merck Sharp and Dohme Research Laboratories
1548674	13	New modified heterocyclic phenylalanine derivatives. Incorporation into potent inhibitors of human renin.	Wyeth-Ayerst Research
1495010	19	Inhibitors of human renin with C-termini derived from amides and esters of alpha-mercaptoalkanoic acids.	Merck Research Laboratories
1404233	68	Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in P1'.	E. Merck Darmstadt
24072703	64	Structural determinants of Tau aggregation inhibitor potency.	The Ohio State University
10580501	2	Kainate receptors are involved in synaptic plasticity.	University of Bristol
9262370	33	I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.	Neurogen
12498885	9	Neoglycopeptides as inhibitors of oligosaccharyl transferase: insight into negotiating product inhibition.	Massachusetts Institute of Technology
17296300	14	Amphipathic benzoic acid derivatives: synthesis and binding in the hydrophobic tunnel of the zinc deacetylase LpxC.	University of San Francisco